AZN Jan 2024 45.000 call
| Previous close | 31.20 |
| Open | 31.20 |
| Bid | 30.75 |
| Ask | 31.65 |
| Strike | 45.00 |
| Expiry date | 2024-01-19 |
| Day's range | 31.20 - 31.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 32 |
ZacksFDA Panel Endorses AstraZeneca (AZN), Sanofi's RSV Antibody
The FDA's AMDAC unanimously recommends AstraZeneca (AZN)/Sanofi's (SNY) nirsevimab as full immunization against RSV disease for all infants.
- Financial Times
UK cell therapy start-up agrees AstraZeneca partnership worth up to $2bn
One of the most promising UK biotech start-ups, Quell Therapeutics, has signed a research collaboration and licensing deal with AstraZeneca to develop treatments for two autoimmune diseases. The pharma giant will pay Quell $85mn upfront and up to $2bn more if it meets various development and commercialisation milestones over the next few years. The technology developed by Quell allows the manipulation of a patient’s immune response by genetically engineering “regulatory T-cells” or Tregs.
ZacksAstraZeneca (AZN) Anticoagulant Drug Study Meets Efficacy Goal
At the interim analysis, AstraZeneca's (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding with targeted anticoagulation reversal versus usual care.
ZacksWhy Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Business WireDatopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
WILMINGTON, Del., June 05, 2023--Updated results from the TROPION-Lung02 Phase Ib trial showed, with additional enrolment and follow-up from the initial presentation, that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum-based chemotherapy demonstrated promising clinical activity and no new safety signals in both previously untreated or pretreated patients with advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterat
Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors
WILMINGTON, Del., June 05, 2023--Positive results from an interim analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses across a broad range of HER2-expressing advanced solid tumors in previously treated patients.
Business WireANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care
WILMINGTON, Del., June 05, 2023--ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of ANDEXXA (andexanet alfa) in patients on oral FXa inhibitor treatment including apixaban and rivaroxaban experiencing an intracranial hemorrhage, will be stopped early.1 The decision is based on achieving pre-specified stopping criteria of superior hemostatic efficacy, the ability to limit the expansion of a potentially life-threatening bleed in the brain, versus usual care.1,2
ReutersAstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients
AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed. The drug has regulatory approvals across multiple geographies for certain patients with so-called non small cell lung cancer (NSCLC) who have a mutation of the EGFR gene. The latest data, presented at the American Society of Clinical Oncology (ASCO) meeting, establishes Tagrisso as the backbone treatment for EGFR-mutated lung cancer, said Susan Galbraith, executive VP of oncology R&D at AstraZeneca in a statement.
Business WireTAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
WILMINGTON, Del., June 04, 2023--Positive results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.
- Financial Times
AstraZeneca defies geopolitics to bet on China
AstraZeneca’s chief executive returned from a recent trip to China exuberant about an “explosion” of biotech companies in the country and the potential for his business to deliver drugs discovered there to the world. Pascal Soriot said the market was “completely open” for pharma investment. “It’s hard to not be impressed by the progress that has been made in China over the last few years,” he added on a press call in April.
Business WireLYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial
WILMINGTON, Del., June 03, 2023--Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA® (olaparib), IMFINZI® (durvalumab), chemotherapy and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus chemotherapy plus bevacizumab (control arm) in newly diagnosed patients with advanced high-grade epithelial ovarian cancer without tumor BRCA mutation
Business WireIMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial
WILMINGTON, Del., June 02, 2023--Positive high-level results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca’s IMFINZI® (durvalumab) added to standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) neoadjuvant (before surgery) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of pathologic complete response (pCR) versus neoadjuvant chemotherapy alone fo
ZacksTop Research Reports for Exxon Mobil, AstraZeneca & Netflix
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), AstraZeneca PLC (AZN) and Netflix, Inc. (NFLX).
- Zacks
FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer
Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC.
ZacksIonis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study
Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.
ZacksPharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies
FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer
ZacksHere's Why Astrazeneca (AZN) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Motley Fool3 Nasdaq 100 Stocks That Are Surefire Buys in June
These phenomenal businesses have the tools and intangibles to make patient shareholders a lot richer.
ZacksAstraZeneca (AZN) Discontinues Brazikumab Development
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
Business WireLYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
WILMINGTON, Del., June 01, 2023--AstraZeneca and Merck & Co., Inc’s, known as MSD outside the US and Canada, LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the US for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
- Zacks
AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal
AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.
Motley FoolWant to Grow Richer? These Stocks Have Doubled in the Past 5 Years
Shares of AstraZeneca (NASDAQ: AZN) and Merck (NYSE: MRK) have both more than doubled over the last five years. With a $228 billion market capitalization, AstraZeneca is the sixth-largest pharmaceutical company in the world and the second-biggest international-based drugmaker behind Novartis (NYSE: NVS). As you'd guess would be the case for a major player in the pharmaceutical industry, the British drugmaker possesses a remarkable product portfolio.
Business WireIMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
WILMINGTON, Del., May 26, 2023--Positive high-level results from the DUO-E Phase III trial showed IMFINZI® (durvalumab) in combination with platinum-based chemotherapy followed by either IMFINZI plus LYNPARZA® (olaparib) or IMFINZI alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cance
Business WireAstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
WILMINGTON, Del., May 25, 2023--AstraZeneca advances its ambition to revolutionize cancer care with new data across its industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6, 2023.
Business WireNew AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD
WILMINGTON, Del., May 23, 2023--Results from the EROS real-world retrospective study showed that initiating fixed-dose triple-combination therapy BREZTRI AEROSPHERE® (budesonide/glycopyrronium/formoterol fumarate) within 30 days of a qualifying moderate or severe exacerbation in patients with COPD (chronic obstructive pulmonary disease) is associated with a decreased risk of future exacerbations by 24% vs. delaying treatment by one to six months, and by 34% vs. delaying treatment six months to o
